SA
CRIS logo
Curis, Inc.(CRIS)
Closing price · checked 8:20 PM ETAbout this dataData status
$0.43▼-0.04 (-9.03%)
Extended:$0.44+0.01 (+2.90%)· 8:20 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Curis, Inc. is a biotechnology company focused on the development of innovative drug therapies for the treatment of cancer. Its lead product candidate, CUDC-907, targets both cancer cell metabolism and epigenetic regulation, positioning the company in a niche market within oncology. The company's competitive advantage lies in its proprietary drug development platform and its focus on rare cancers, which are often underserved by larger pharmaceutical firms.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and regulatory compliance, which limits its operating leverage.

Business Overview

01Product sales from CUDC-907 (estimated 100% of total revenue)
02Collaborative agreements (if applicable, but currently minimal)

Curis generates revenue primarily through the sale of its cancer therapies, particularly CUDC-907. The company has established partnerships with larger pharmaceutical companies for co-development and commercialization, which provides additional funding and market access. Its competitive advantage stems from its focus on unique mechanisms of action and the ability to address unmet medical needs in oncology.

What Moves the Stock

Clinical trial results for CUDC-907, particularly Phase 2 outcomes

Partnership announcements with larger pharmaceutical companies

Regulatory approvals from the FDA or EMA

Market adoption rates of CUDC-907 post-launch

Watch on Earnings
Clinical trial enrollment numbersCash burn ratePartnership revenue contributions

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption in cancer treatment methodologies

Emergence of new therapies that could outperform CUDC-907

Increased competition from larger biotech firms with more resources

High cash burn rate impacting liquidity

Potential for dilution if additional equity financing is required

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The demand for oncology treatments is less sensitive to economic cycles as cancer treatment is often a necessity.

Interest Rates

Moderate - Rising interest rates can increase the cost of capital for R&D funding, potentially impacting the company's ability to finance its operations.

Credit

minimal - Curis has a low debt-to-equity ratio, indicating limited reliance on credit markets.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors interested in high-risk, high-reward opportunities in the biotech sector.

high - The stock has experienced significant volatility, particularly in response to clinical trial results and regulatory news.

Key Metrics to Watch
Clinical trial enrollment rates for CUDC-907
Cash burn rate
Partnership revenue contributions
FDA approval timelines for pipeline products
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.